Home
→
Browsing by Author

Browsing by Author "Rubio-Rodríguez, Darío"

Now showing items 1-5 of 5

Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature

Grau Cerrato, Santiago; Miró, José María; Olalla, Julian; Alcalá, Juan C.; Castro, Antonio; Rubio-Rodríguez, Darío; Rubio-Terrés, Carlos (Taylor & Francis, 2023)

Introduction: Current recommended antiretroviral regimens include a combination of two (dual; DT) or three (triple; TT) antiretroviral drugs. This study aims to determine whether the quality of evidence from clinical trials ...
Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain

Grau Cerrato, Santiago; Azanza Perea, José Ramon; Ruiz, Isabel; Vallejo, Carlos; Mensa, Josep; Maertens, Johan; Heinz, Werner; Barrueta, Jon Andoni; Peral, Carmen; Mesa, Francisco Jesús; Barrado, Miguel; Charbonneau, Claudie; Rubio-Rodríguez, Darío; Rubio-Terrés, Carlos (Dove Medical Press, 2016)

OBJECTIVE: According to a recent randomized, double-blind clinical trial comparing the combination of voriconazole and anidulafungin (VOR+ANI) with VOR monotherapy for invasive aspergillosis (IA) in patients with hematologic ...
Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients.

Grau Cerrato, Santiago; Romá, E.; Salavert, M.; Barrueta, Jon Andoni; Peral, Carmen; Rodriguez, I.; Rubio-Rodríguez, Darío; Rubio-Terrés, Carlos (Auckland, NZ : Dove Medical Press, 2015)

OBJECTIVE: To estimate the cost-effectiveness of three echinocandins (anidulafungin, caspofungin, and micafungin) and generic fluconazole in the treatment of nonneutropenic adult patients with candidemia and/or invasive ...
Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

Isla, Dolores; De Castro, Javier; Juan, Oscar; Grau Cerrato, Santiago; Orofino, Javier; Gordo, Rocío; Rubio-Terrés, Carlos; Rubio-Rodríguez, Darío (Dove Medical Press, 2016)

OBJECTIVES: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an established treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutation. According to published meta-analyses, no ...
Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain

Rubio-Terrés, Carlos; Aguado, José María; Almirante, Benito; Cobo, Javier; Grau Cerrato, Santiago; Salavert, M.; González Antona Sánchez, Elena; López Gutiérrez, Cristina; Rubio-Rodríguez, Darío (SpringerOpen, 2019)

The cost of treating Clostridium difficile infection (CDI) in Spain is substantial. Findings from the randomised, controlled, open-label, phase 3b/4 EXTEND study showed that an extended-pulsed fidaxomicin (EPFX) regimen ...

Now showing items 1-5 of 5

Search DSpace

Advanced Search

Browse

All of DSpace

My Account

Compliant to Partaking

Browsing by Author "Rubio-Rodríguez, Darío"

Browsing by Author "Rubio-Rodríguez, Darío"

Search DSpace

Browse

All of DSpace

My Account